P
Passage Bio, Inc. (PASG)
NCM – Real vaqt narxi. Valyuta: USD
4.70
+0.37 (8.55%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.56
-0.14 (-2.90%)
Bozordan keyin: Jun 26, 2026, 7:46 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
4.70
+0.37 (8.55%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.56
-0.14 (-2.90%)
Bozordan keyin: Jun 26, 2026, 7:46 PM EDT
Passage Bio, Inc., gen terapiyasi kompaniyasi, markaziy asab tizimi kasalliklari uchun gen terapiyasini ishlab chiqadi. U progranulin etishmovchiligidan kelib chiqqan FTDni davolash uchun funktsional granulini (GRN) va progranulin (PGRN) kodlovchi genni PBFT02ni ishlab chiqadi; chaqaloq GM1 uchun β-galaktosidazni kodlovchi funktsional GLB1 genini PBGM01ni; va Krabbe kasalligini davolash uchun PBKR03ni ishlab chiqadi. Kompaniya metakromatik leyko distrofiyasini davolash uchun PBML04ni; amiotrofik lateral sklerozni davolash uchun PBAL05ni; va Huntington kasalligi uchun boshqa dasturlarni ishlab chiqadi. U Pensilvaniya universiteti gen terapiyasi dasturining vasiylari bilan strategik tadqiqot hamkorligiga ega; hamda Catalent Maryland, Inc. bilan hamkorlik shartnomasi va ishlab chiqish xizmatlari va klinik ta'minot shartnomasiga ega. Passage Bio, Inc. 2017 yilda tashkil etilgan va Filadelfiya, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Stuart M. Henderson | Chief Business Officer |
| Ms. Kathleen Borthwick | Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-24 | 425 | tm2618476d3_425.htm |
| 2026-05-27 | 8-K | pasg-20260521x8k.htm |
| 2026-05-26 | 8-K | tm2615548d1_8k.htm |
| 2026-05-12 | 10-Q | pasg-20260331x10q.htm |
| 2026-04-28 | 8-K | tm2612859d1_8k.htm |
| 2026-04-20 | 8-K | tm2612152d1_8k.htm |
| 2026-04-07 | DEFA14A | pasg-20260407xdefa14a.htm |
| 2026-04-07 | ARS | pasg-20251231xars.pdf |
| 2026-03-10 | 8-K | tm268398d1_8k.htm |
| 2026-03-04 | S-8 | tm267647d1_s8.htm |